Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
8-K
Other Events
10 Apr 24
8-K
Cost Associated with Exit or Disposal Activities
4 Apr 24
8-K
Departure of Directors or Certain Officers
14 Mar 24
8-K
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX
8 Mar 24
S-8
Registration of securities for employees
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 24
UPLOAD
Letter from SEC
20 Dec 23
CORRESP
Correspondence with SEC
19 Dec 23
8-K
Regulation FD Disclosure
7 Dec 23
UPLOAD
Letter from SEC
5 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Other Events
13 Oct 23
S-8
Registration of securities for employees
10 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
10 Aug 23
8-K
Other Events
26 Jul 23
8-K
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation
23 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results
11 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
8-K
Departure of Directors or Certain Officers
21 Mar 23
S-8
Registration of securities for employees
13 Mar 23
S-3ASR
Automatic shelf registration
13 Mar 23
10-K
2022 FY
Annual report
13 Mar 23
8-K
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
13 Mar 23
8-K
Regulation FD Disclosure
14 Feb 23
8-K
Entry into a Material Definitive Agreement
6 Dec 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
10 Nov 22
8-K
Departure of Directors or Certain Officers
2 Nov 22
424B4
Prospectus supplement with pricing info
7 Oct 22
EFFECT
Notice of effectiveness
7 Oct 22
Latest ownership filings
4
JAMES M FRATES
18 Apr 24
4
Joshua B Cohen
18 Apr 24
4
Gina Mazzariello
18 Apr 24
4
Justin B. Klee
18 Apr 24
4
Camille L Bedrosian
18 Apr 24
4
Bernhardt G Zeiher
15 Mar 24
3
Bernhardt G Zeiher
15 Mar 24
SC 13G
Panacea Innovation Ltd
11 Mar 24
4
Joshua B Cohen
7 Mar 24
4
Justin B. Klee
7 Mar 24
4
JAMES M FRATES
7 Mar 24
4
Gina Mazzariello
7 Mar 24
4
JAMES M FRATES
28 Feb 24
4
Joshua B Cohen
28 Feb 24
4
Justin B. Klee
28 Feb 24
4
Gina Mazzariello
28 Feb 24
4
Gina Mazzariello
27 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
BlackRock Inc.
29 Jan 24
4
GEORGE M MILNE JR
29 Jan 24
4
GEORGE M MILNE JR
18 Jan 24
4
Justin B. Klee
11 Jan 24
4
JAMES M FRATES
11 Jan 24
4
Joshua B Cohen
11 Jan 24
4
Patrick D Yeramian
11 Jan 24
4
Margaret Olinger
29 Dec 23
4
Karen Firestone
19 Dec 23
SC 13G
Point72 Asset Management, L.P.
11 Dec 23
4
Camille L Bedrosian
29 Nov 23
3
Camille L Bedrosian
29 Nov 23
4
Joshua B Cohen
20 Nov 23
4
JAMES M FRATES
2 Nov 23
SC 13D/A
Morningside Venture Investments Ltd
4 Oct 23
4
JAMES M FRATES
24 Aug 23
4
Change in insider ownership
17 Aug 23
SC 13D/A
Morningside Venture Investments Ltd
17 Aug 23
4
Gina Mazzariello
17 Aug 23